MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog.
MIRA藥品公司（NASDAQ:MIRA）股價週一上漲，原因是公司發佈了關於Ketamir-2的新臨床前研究結果，該產品是一種新型口服氯胺酮類似物。
The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain.
新的臨床前數據顯示，Ketamir-2在減輕化療引起的疼痛方面比FDA批准的神經病痛治療加巴噴丁更有效，效果提高了60%。
The study used the paclitaxel (PTX) model, in which a common chemotherapy drug, PTX, was administered to mice to induce neuropathic pain.
該研究使用紫杉醇（PTX）模型，在此模型中，向小鼠注射一種常見的化療藥物PTX，以誘發神經病痛。
Also Read: MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
還閱讀：MIRA藥品公司的口服氯胺酮類似物在動物研究中實現神經病痛完全正常化
While effective in treating cancer, PTX often causes nerve damage, leading to chemotherapy-induced neuropathy characterized by pain, numbness, and tingling.
儘管紫杉醇在治療癌症方面有效，但常常導致神經損傷，進而引發化療誘導的神經病痛，表現爲疼痛、麻木和刺痛。
To assess Ketamir-2's efficacy, mice received PTX every other day for four doses, and pain sensitivity was measured using the Von Frey filament (VFF) test.
爲評估Ketamir-2的療效，小鼠每隔一天接受PTX四次劑量，並使用Von Frey細絲（VFF）測試來測量疼痛敏感度。
On Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provided only moderate relief.
在第9天，以最佳劑量300毫克/千克計算，Ketamir-2使疼痛敏感度幾乎完全正常化，表現出比FDA批准的加巴噴丁高出60%的性能，後者僅提供中等緩解。
The company will present these findings and data from previous studies at the upcoming Pain Therapeutics Summit.
公司將在即將舉行的疼痛治療峯會上介紹這些發現以及先前研究的數據。
The company is preparing to submit an Investigational New Drug (IND) application by the end of 2024, with plans to begin Phase I clinical trials in the first quarter of 2025.
該公司計劃在2024年底前提交新藥開發申請(IND)，並計劃於2025年第一季度開始I期臨床試驗。
To maximize the development timeline, MIRA is considering conducting multiple Phase 2 trials in parallel, specifically targeting neuropathic pain across different patient populations, which could further accelerate Ketamir-2's path to market.
爲了最大程度地優化開發時間表，MIRA正在考慮同時進行多項II期臨床試驗，重點瞄準不同患者群體中的神經病性疼痛，這可能進一步加快Ketamir-2上市的步伐。
In addition to the ongoing studies, MIRA is in the process of submitting several scientific journal publications that detail Ketamir-2's mechanism of action, as well as the results from its pain and depression studies.
除了正在進行的研究，MIRA正在準備提交幾篇詳細介紹Ketamir-2作用機制以及疼痛和抑鬱症研究結果的科學期刊論文。
Furthermore, Ketamir-2 is under evaluation for post-traumatic stress disorder (PTSD), with preclinical studies currently underway.
此外，Ketamir-2正在接受創傷後應激障礙(PTSD)的評估，目前正在進行臨床前研究。
MIRA is actively seeking government grants to support research on PTSD and other indications.
MIRA正在積極尋求政府撥款以支持對PTSD和其他適應症的研究。
Price Action: MIRA stock is up 40.30% at $1.81 at the last check on Monday.
股價走勢：MIRA股價在上週一最後檢查時上漲了40.30%，報價1.81美元。
- EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
- EyePoint的研究性藥物顯示出比Regeneron的Eylea在糖尿病相關視力喪失方面更早和持續的改善
譯文內容由第三人軟體翻譯。
